Market Overview

UPDATE: Oppenheimer Initiates Kamada at Outperform on Pioneering Inhaled Delivery with AAT Treatment

Share:

In a report published on Tuesday, Oppenheimer analyst David Ferreiro initiated coverage on Kamada (NASDAQ: KMDA) with an Outperform rating and a price target of $14.

In the report, Oppenheimer stated, "KMDA's key commercial product is Glassia, an intravenous treatment for alpha-1 antitrypsin (AAT) deficiency, a rare disorder leading to lung disease. The company's key value driver is the development of the first inhaled version of AAT. We believe such a product would be disruptive to current intravenous treatments and expand the overall AAT deficiency market. We estimate inhaled AAT could achieve peak revenues of ~$300M, a significant elevation from KMDA's current revenues of ~$74M."

Kamada closed on Monday at $10.77.

Latest Ratings for KMDA

DateFirmActionFromTo
Feb 2018Chardan CapitalInitiates Coverage OnBuy
Nov 2015JefferiesMaintainsBuy
Jun 2013JefferiesInitiates Coverage onBuy

View More Analyst Ratings for KMDA
View the Latest Analyst Ratings

 

Related Articles (KMDA)

View Comments and Join the Discussion!

Posted-In: David Ferreiro OppenheimerAnalyst Color Initiation Analyst Ratings

Latest Ratings

StockFirmActionPT
TYGB of A SecuritiesUpgrades
ZIONB of A SecuritiesMaintains39.0
RFB of A SecuritiesMaintains13.0
PNCB of A SecuritiesMaintains123.0
HBANB of A SecuritiesMaintains11.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Premarket Activity
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Fintech Focus
A daily collection of all things fintech, interesting developments and market updates.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com